Table 1 Patient summary
Patient ID | Age | Tumour type | Prior treatment | Disease status at inclusion |
|---|---|---|---|---|
IRS 11 | 70 | Papillary serous cystadenocarcinoma | Surgery, 2 lines chemo, | Progessive disease (PD) with rising CA125 |
IRS 12 | 79 | Papillary serous cystadenocarcinoma | Surgery, 2 lines chemo, | PD – with progressive nodal abnormalities above and below diaphragm and new peritoneal abdo/pelvic disease |
IRS 13 | 69 | Papillary serous cystadenocarcinoma | Surgery, 2 lines chemo, | PD with short bowel syndrome |
BLV 01 | 74 | Ovarian carcinoma | Surgery, 3 lines chemo | PD with newly formed hepatic lesion, hepatogastric, lymph node, peritoneal and mesenteric lesions present |
BLV 02 | 80 | Ovarian carcinoma | Surgery, 3 lines chemo, provera | PD with increase of peritoneal metastases with ascites formation |
BLV 03 | 73 | Ovarian carcinoma | 3x surgery, 4 lines chemo | PD with increase and new formation of abdominal metastases and possible lymph node metastases |
BLV 04 | 64 | Peritoneal tumour | Surgery, 6 lines chemo, avastin | PD with peritoneal, omental, vertebral, hepatic and possible gastric metastases |
BLV 05 | 62 | Endometrial carcinoma | 2x surgery, 1 line chemo, radiotherapy | PD with increase of hepatic, brain and possible renal metastases |
BLV 06 | 74 | Malignant mixed Müllerian tumour (MMMT) | Surgery, 1 line chemo | PD with increase of known retroperitoneal lesions and occurrence of a new lesion |
BLV 07 | 82 | Ovarian carcinoma | 2x surgery, 5 lines chemo, provera | PD with increase of LN metastases in upper abdomen, metastases in mediastinum and formation of lung metastases |
IRS 01 | 43 | Adenocarcinoma | Surgery, 1 line chemo, radiotherapy and EGFR inhibitor | PD with recurrence in supraclavicular fossa lymph node |
IRS 02 | 45 | Ovarian carcinoma | Surgery, 3 lines chemo, radiotherapy | PD with hepatic involvement |
IRS 03 | 54 | Papillary serous cystadenocarcinoma | Surgery, 2 lines chemo, radiotherapy | PD with rising CA-125 marker |
IRS 04 | 63 | Papillary serous cystadenocarcinoma | Surgery, 5 lines chemo, hormone therapy | PD with rising CA-125 marker |
IRS 05 | 68 | Serous cystadenocarcinoma | 2x Surgery, 1 line chemo, hormone therapy | PD with rising CA-125 marker |
IRS 06 | 74 | Papillary serous cystadenocarcinoma | Surgery, 2 lines chemo | PD rising CA-125 marker, PAN and adrenal gland involvement |
IRS 07 | 66 | Papillary serous cystadenocarcinoma | Surgery, 3 line chemo, radiotherapy, 1x EGFR inhibitor | PD with rising CA125 |
IRS 08 | 63 | Papillary serous cystadenocarcinoma | Surgery, 2 lines chemo | PD with rising CA125 level |
IRS 09 | 63 | Papillary serous cystadenocarcinoma | Surgery, 5 lines chemo | PD with omental mass increased in size |